(Cervical Cancer) Is Cemiplimab Effective? EMPOWER-Cervical 1 Phase 3 Trial Results
Medical Supporter — Мэдээллийн мэдэгдэл
Энэ нийтлэл нь олон улсын эмнэлгийн мэдээллийн эмхэтгэл бөгөөд эмнэлгийн зөвлөгөө биш; таны эмчийн оношлогоо, эмчилгээний төлөвлөгөөг орлохгүй. Энд буй мэдээлэл нь Японы томоохон эмнэлгийн байгууллагуудын нээлттэй эх сурвалжаас эмхэтгэсэн бөгөөд аливаа эмчилгээний тохиромж, үр дүн өвчтөн бүрээр өөр тул мэргэшсэн эмч тус бүрчлэн үнэлэх ёстой.
- June 7, 2021
- 2 min read
The EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 Phase 3 clinical trial evaluated cemiplimab (anti-PD-1 antibody) versus investigator's choice of chemotherapy in patients with recurrent cervical cancer who had progressed on prior platinum-based therapy. Results were published in the New England Journal of Medicine.
Trial Design:
Patients with recurrent, metastatic, or persistent cervical cancer who had progressed on prior platinum-containing chemotherapy were randomized to receive either cemiplimab 350 mg IV every 3 weeks or investigator's choice of single-agent chemotherapy (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed). The primary endpoint was overall survival (OS).
Results:
- Median OS: Cemiplimab 12.0 months vs. chemotherapy 8.5 months
- Hazard ratio: 0.69 (31% reduction in death risk)
- The OS benefit was observed regardless of PD-L1 expression status
Conclusion: Based on the EMPOWER-Cervical 1 trial results, cemiplimab demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to chemotherapy in patients with recurrent cervical cancer following platinum-based therapy.
Disclaimer: Medical Supporter translates overseas clinical trial data and pharmaceutical information for informational purposes only. Please consult your healthcare provider for medical decisions.
Source: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9. N Engl J Med. 2021.
Cervical Cancer | Immunotherapy | Cemiplimab
-
Clinical Trial Medications
-
Immunotherapy
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Японд эмчлүүлэхээр төлөвлөж байна уу? Мэдээлэл, тусламж хэрэгтэй юу?
Бид Японд эмчлүүлэхэд шаардлагатай мэдээллийг эмхэтгэх, Японы эмнэлгийн байгууллагуудтай холбогдох, хоёр дахь саналын зөвлөгөө зохион байгуулахад тусална.Анхны зөвлөгөө үнэгүй; зөвлөх таны дараагийн алхмыг тодорхой болгоход тусална.
Figure 1
Figure 2
Figure 3
Figure 4